Fluorescence polarization-based assay using N-glycan-conjugated quantum dots for screening in hemagglutinin blockers for influenza A viruses

Okamatsu, Masatoshi; Fěng, Fang; Ohyanagi, Tatsuya; Nagahori, Noriko; Someya, Kazuhiko; Sakoda, Yoshihiro; Miura, Nobuaki; Nishimura, Shin‐Ichiro; Kida, Hiroshi

doi:10.1016/j.jviromet.2012.11.004

Cited by 12 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biantennary N -glycan-α- sialoside labeled quantum dot (QD-A2PC) was used to screen and discover novel hemagglutinin (HA) inhibitors for use in anti-influenza drugs. 25 The assay involved BroHA residue, which binds sialic acid derivatives, of X-31 viral strain. The sialic acid ligands on the glyco-nanoprobe and synthetic compounds compete with each other for BroHA.…”

Section: Analyticalmentioning

confidence: 99%

Glyco-nanotechnology: A biomedical perspective

Kalita

Payne

Bossmann

2022

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

Section: Analyticalmentioning

confidence: 99%

Glyco-nanotechnology: A biomedical perspective

Kalita

Payne

Bossmann

2022

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

“…To develop anti-influenza small molecule drugs, an FA assay with targeted QDs that have high affinity for the viral protein hemagglutinin (HA) has been designed. 92 In another study, Zhang et al 93 developed FA sensitive QD based probes for H1N1 (swine flu) detection.…”

Section: Novel Applications: Biologics Nanotechnology and Imaginmentioning

confidence: 99%

Fluorescence anisotropy (polarization): from drug screening to precision medicine

Zhang

Berezin

2015

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction Fluorescence anisotropy (FA) is one of the major established methods accepted by industry and regulatory agencies for understanding the mechanisms of drug action and selecting drug candidates utilizing a high-throughput format. Areas covered This review covers the basics of FA and complementary methods, such as fluorescence lifetime anisotropy and their roles in the drug discovery process. The authors highlight the factors affecting FA readouts, fluorophore selection, and instrumentation. Furthermore, the authors describe the recent development of a successful, commercially valuable FA assay for Long QT syndrome drug toxicity to illustrate the role that FA can play in the early stages of drug discovery. Expert opinion Despite the success in drug discovery, the FA-based technique experiences competitive pressure from other homogeneous assays. That being said, FA is an established yet rapidly developing technique, recognized by academic institutions, the pharmaceutical industry, and regulatory agencies across the globe. The technical problems encountered in working with small molecules in homogeneous assays are largely solved, and new challenges come from more complex biological molecules and nanoparticles. With that, FA will remain one of the major work-horse techniques leading to precision (personalized) medicine.

show abstract

“…However the affinity of HA for these sialosides is low and presented a hurdle in the application of these assays. In a recent advancement, novel fluorescent nanoparticles consisting of quantum dots with sialylated N-glycan chains present a feasible option for the screening of influenza attachment inhibitors in FP-type high-throughput assays (Marron and Jayawickreme, 2003; Okamatsu et al, 2013). Surface plasmon resonance (SPR) has been shown to be amenable to HTS (Piliarik et al, 2005) and in 1996, SPR was used to probe the interaction between HA and its receptor (Palese and Shaw, 2007; Takemoto et al, 1996), while more recently it has been used to screen for RNA aptamers that bind HA (Hooker et al, 2001; Misono and Kumar, 2005).…”

Section: Cell-free Assays For Viral Proteinsmentioning

confidence: 99%

New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions

et al. 2013

View full text Add to dashboard Cite

Current options for influenza antiviral therapy are limited to the neuraminidase inhibitors, and knowledge that high levels of oseltamivir resistance have been seen amongst previously circulating H1N1 viruses increases the urgency to find new influenza therapeutics. To feed this pipeline, assays that are appropriate for use in high-throughput screens are being developed and are discussed in this review. Particular emphasis is placed on cell-based assays that capture both inhibitors of viral functions as well as the host functions that facilitate optimal influenza virus replication. Success in this area has been fueled by a greater understanding of the genome structure of influenza viruses and the ability to generate replication-competent recombinant viruses that carry a reporter gene, allowing for easy monitoring of viral infection in a high-throughput setting. This article forms part of a symposium in Antiviral Research on “Treatment of influenza: targeting the virus or the host.”

show abstract

Fluorescence polarization-based assay using N-glycan-conjugated quantum dots for screening in hemagglutinin blockers for influenza A viruses

Cited by 12 publications

References 30 publications

Glyco-nanotechnology: A biomedical perspective

Glyco-nanotechnology: A biomedical perspective

Fluorescence anisotropy (polarization): from drug screening to precision medicine

New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions

Contact Info

Product

Resources

About